Drug Patents

Pharmaceutical companies use multiple types of patents to build layered protection around drugs: (1) COMPOSITION-OF-MATTER PATENTS (STRONGEST): covers the active ingredient (API) itself; claim the specific chemical structure; example: 'A compound of formula [X] or a pharmaceutically acceptable salt thereof'; provides the broadest protection — covers the molecule itself regardless of indication, formulation, or dosing; the composition patent is the 'primary' drug patent; expires 20 years from filing; may be extended under § 156 patent term extension; (2) FORMULATION PATENTS: covers the specific pharmaceutical formulation (tablet, capsule, extended-release, injectable); excipients, polymer coatings, delivery systems; example: nanoparticle formulation for poorly soluble compound; extended-release matrix technology; these patents often have longer terms than the composition patent — filed later during development; (3) METHOD-OF-USE PATENTS (METHOD OF TREATMENT): covers specific indications and dosing regimens; 'A method of treating [disease] comprising administering [compound] to a patient in need thereof at a dose of [X] mg'; can be filed for new indications (new use for old compound); method patents are protected by FDA use codes in the Orange Book; generic must design around method patents or certify non-infringement; (4) METABOLITE PATENTS: covers the active metabolite (breakdown product) of a prodrug; extends protection when the metabolite is the actual active species; (5) PROCESS/MANUFACTURING PATENTS: covers the specific synthesis process; harder for generic companies to practice if process is patented; less common now due to process invalidity/prior art exposure; (6) SALT/POLYMORPH PATENTS: covers specific salt forms, crystalline polymorphs; criticized as evergreening — same molecule, different form.

FDA exclusivity is a separate protection from patents — both can extend market exclusivity concurrently or sequentially: NEW CHEMICAL ENTITY (NCE) EXCLUSIVITY: 5 years from approval for drugs with a new active ingredient never before approved; during NCE exclusivity: FDA cannot accept an ANDA or 505(b)(2) application; no generic application filing for 5 years; the 5-year exclusivity starts at NDA approval, not at patent filing; runs in parallel with patent protection; NEW CLINICAL INVESTIGATION EXCLUSIVITY: 3 years from approval for applications requiring new clinical investigations (new indication; new formulation; new population); applies to changes to already-approved drugs; prevents FDA from approving ANDA relying on the new data for 3 years; ORPHAN DRUG EXCLUSIVITY: 7 years from approval for drugs designated to treat rare diseases (fewer than 200,000 US patients); the most powerful exclusivity — blocks FDA from approving the same drug for the same indication for 7 years; PEDIATRIC EXCLUSIVITY: 6 months additional exclusivity added to all existing patents and exclusivities for drugs tested in children; highly valuable — 6 months of exclusivity on a blockbuster drug = hundreds of millions of dollars; requires completion of FDA-requested pediatric studies; PRIORITY REVIEW VOUCHER (PRV): transferable vouchers granted for developing drugs for neglected diseases or rare pediatric diseases; entitles holder to priority FDA review (6 months instead of standard 12 months); tradeable — sold for $100M+; HOW THESE LAYER: a compound-of-matter patent expiring in 2030; NCE exclusivity expires 2025; formulation patents expire 2032; pediatric exclusivity adds 6 months on ALL patents and exclusivities; total protected period = sum of all overlapping and sequential protections.

The composition-of-matter patent is the cornerstone pharmaceutical patent and interacts specifically with the regulatory framework: COMPOSITION PATENT FILING TIMELINE: filed during discovery/lead optimization phase (5-10+ years before approval); by the time the drug is approved, 8-12 years of 20-year patent term may already be used; effective patent life after approval may only be 8-12 years; PATENT TERM EXTENSION (§ 156): available to restore up to 5 years of patent term lost to regulatory review; maximum remaining term after restoration: 14 years from NDA approval; calculates: the regulatory review period (time from IND filing to NDA approval) divided by 2, up to 5 years maximum extension; ONLY ONE PATENT may receive patent term extension for a given drug; must be the patent that claims the approved product or method of using it; applied for within 60 days of NDA approval; PATENT TERM RESTORATION APPLICATION: filed with the USPTO; the FDA certifies the regulatory review period; the USPTO calculates and grants the extension; CERTIFICATE OF EXTENSION: specifies the extended term; limits the extended claims to those covering the approved product; INTERACTION WITH NCE EXCLUSIVITY: a drug with NCE exclusivity gets 5 years of FDA exclusivity from approval; the composition patent's extended term may cover longer than 5 years from approval; they overlap — during NCE exclusivity, FDA won't even accept ANDA applications; after NCE exclusivity expires, the composition patent (now extended) still blocks ANDA approval; PARAGRAPH IV CHALLENGES: generic applicants may challenge the composition patent at any time; but if within NCE exclusivity, FDA won't accept the ANDA; typically generics file ANDA + Paragraph IV certification 4 years into NCE exclusivity (because of the 1-year safe harbor for early Paragraph IV filings).

Generic drug manufacturers have multiple tools for challenging branded drug patents: HATCH-WAXMAN ANDA PARAGRAPH IV CERTIFICATION: the primary mechanism for generic patent challenges; generic files an ANDA with an FDA certification that: Paragraph I: patent does not exist; Paragraph II: patent has expired; Paragraph III: generic will launch after patent expires (no challenge); Paragraph IV: patent is invalid or will not be infringed by the generic; PARAGRAPH IV PROCEDURE: generic applicant notifies the brand; brand must file suit within 45 days; 30-month stay of FDA approval; litigation proceeds; INTER PARTES REVIEW (IPR): post-grant challenge at PTAB; 1-year filing deadline from complaint service; prior art grounds only; faster than district court; widely used by generic companies to invalidate branded drug patents; INVALIDITY ARGUMENTS IN PHARMA: obviousness: most common; is the drug structurally obvious over known compounds?; lead compound analysis; structural similarity + motivation to modify; unexpected results defense; anticipation: prior art patents or publications disclosing the compound; enablement/written description: can a POSITA make the full scope of claims?; obviousness-type double patenting (ODP): related compound in overlapping patent; terminal disclaimer required; INEQUITABLE CONDUCT: prior art withheld from USPTO during prosecution; particularly damaging if found — renders patent unenforceable; DESIGN-AROUND: generic develops alternative formulation not covered by branded patents; alternative synthesis not infringing process patents; different salt or polymorph not covered by salt/polymorph patents; AT-RISK LAUNCH CONSIDERATIONS: generic can launch after 30-month stay without court decision; exposure to lost profits damages; depends on patent strength assessment; REVERSE PAYMENT SETTLEMENTS: brand pays generic to delay market entry; FTC v. Actavis (S.Ct. 2013): reverse payments subject to antitrust rule of reason scrutiny.

Evergreening refers to strategies used to extend pharmaceutical market exclusivity beyond the original patent term: COMMON EVERGREENING STRATEGIES: (a) NEW FORMULATION PATENTS: extended-release formulations; new dosing schedules; new delivery devices (autoinjectors, inhalers); (b) METABOLITE PATENTS: patenting the active metabolite; (c) NEW INDICATION PATENTS: patenting newly discovered uses for the same active ingredient; (d) POLYMORPH PATENTS: patenting a specific crystalline form of the compound; (e) COMBINATION PRODUCT PATENTS: patenting a fixed-dose combination with another drug; (f) SALT FORM PATENTS: patenting a new salt form with improved properties; LEGAL ANALYSIS: evergreening strategies are generally legal; secondary patents are patentable if novel and non-obvious; the question is whether they add genuine innovation vs. minor variants; many secondary patents are challenged by generics in Paragraph IV litigation; POLICY DEBATE: pharmaceutical companies argue evergreening funds additional R&D; generics and payers argue evergreening delays generic entry and harms patients; academic studies: mixed results on whether evergreening significantly delays generic entry; INTERNATIONAL POLICY RESPONSES: India: Patents Act § 3(d): patentability of new forms of known substances requires showing enhanced efficacy; specifically designed to prevent evergreening; blocks most salt/polymorph/new formulation patents for existing drugs; Canada: special regulatory considerations; EU: European Patent Offices allows secondary patents but with narrower scope; UNITED STATES: no § 3(d) equivalent; secondary patents are generally allowed if they meet novelty and non-obviousness; Hatch-Waxman Paragraph IV is the primary mechanism to challenge; REGULATORY SOLUTIONS: FDA requires generic applicants only to bioequivalence, not to practice every branded patent; design-around options limit evergreening effectiveness.